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Kasper and colleagues (1) have analyzed clinical and histo-
logic data of 673 patients with left ventricular dilation and
reduced contractility who underwent endomyocardial bi-
opsy. They found that the most common diagnostic category
was idiopathic dilated cardiomyopathy . This is not a surpris-
ing finding, although the proportion of patients with specific
diagnoses (53 .5%) is higher than I would have expected .
They were able to make a diagnosis by examination of
histopathologic data in a minority of cases . This also is not a
new finding, but again the proportion of patients seems high
(17% had a diagnostic biopsy) .
I find this to be an especially useful report because it is
based on a uniform set of data in each case, including clinical
history, clinical laboratory tests, echocardiogram, right
heart catheterization and endomyocardial biopsy . The mes-
sage is clearly delivered and almost fully recapitulated in a
single table (Table 2 on page 587) . This report tells me that if
I undertake an evaluation of patients presenting with dilated
cardiomyopathy, the diagnostic yield will be low-once
coronary artery disease has been ruled out-and the rela-
tively few diagnoses I may make will be responsive, for the
most part, only to routine treatment for heart failure .
Incidence of specific diagnoses in dilated cardiornyopathy .
To decide how to apply these findings to our own practice,
each of us must estimate the similarity of this series to the
patients we encounter
. In a conversation with Dr . Kasper I
learned that the majority of the subjects of this report were
referred by cardiologists for management of severe conges-
tive heart failure . Some were suspected to have myocarditis .
Most of the referring physicians knew that an endomyocar-
dial biopsy was likely to be done . Thus, though the series is
consecutive from the authors' viewpoint, it is not consecu-
tive in the sense of being representative of patients seen by
a family practitioner or a general internist. In fact, it proba-
bly is not representative of the patients seen by the referring
physicians themselves, as id contains only those they de-
cided to refer and, importantly, those who would have an
endomyocardial biopsy .
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In all likelihood, not all referred patients in this series
underwent endomyocardial biopsy
. Some patients would
have had a contraindication to biopsy . Some would have
refused the procedure . It would have been technically in-
feasible in others . In some, a risk/benefit analysis surely
would have precluded performing the biopsy
. Therefore, this
report analyzes a series of patients with dilated cardiomy-
opathy referred by cardiologists for management of severe
congestive heart failure in whom endomyocardial biopsy
was considered appropriate and was successfully performed
.
How might this patient population differ from that of "the
real world" in the United States? The average physician
practices in a less densely populated, less metropolitan
setting and so would see fewer patients with cardiomyopathy
related to drug and alcohol abuse and human immunodefi-
ciency virus than are reported in the present series . Fewer
patients with myocarditis and peripartum cardiomyopathy
would be seen in an unselected population, as these disor-
ders were probably concentrated at Johns Hopkins Hospital,
where there is a specific investigative interest in them . There
would also be fewer biopsy diagnoses in the general popu-
lation. Referring physicians and invasive cardiologists select
patients for biopsy who have a higher probability of a
histologic diagnosis on the basis of numerous clinical char-
acteristics, such as a recent viral illness, treatment with
doxorubicin, an echocardiogram suggesting amyloidosis,
recent pregnancy and noncardiac manifestations of sarcoid-
osis, hemochromatosis, amyloidosis and other histologically
definable cardiac disorders . Furthermore, an unselected
population wool
. have less severe congestive failure and
would be less likely to display specific as well as nonspecific
histologic abnormalities on biopsy than those of the patients
reported on by Kasper et al . (1) .
If the average patient with dilated cardiomyopathy comes
to your office today, I believe you have less than the 53 .5%
probability reported in this series of making a specific
etiologic diagnosis. I suspect this probability would be closer
to 20% or 25% in the average population, and the diagnosis
would be apparent in most patients after the history was
taken. A histologic diagnosis (a "positive" biopsy) was
obtained in 17% of patients in the Johns Hopkins study . I
would expect a figure of :s 10% in the general population .
Clinical evaluation of dilated cardiomyopathy . If I am
correct in stating that clinical evaluation of patients with
dilated cardiomyopathy has a low diagnostic yield and an
even lower yield of histologic diagnoses, what should be
included in the assessment? First, the diagnosis of dilated
cardiomyopathy must be made . This requires an echocardio-
gram. Whenever coronary artery disease is a diagnostic
consideration, a coronary arteriogram (not just a noninva-
sive screening test) should be done . Coronary disease may
have been responsible for dilated cardiomyopathy in 11% of
patients in the series of Kasper et al
., even though many _f
them had already been screened for coronary disease by a
cardiologist .
0735-1097/94/$7 .00
592
	
MASON
EDITORIAL COMMENT
With the generic diagnosis of dilated cardiomyopathy
established, is a biopsy required? In general, no .
Why not? Not only is the diagnostic yield of biopsy low,
but the yield of therapeutically important information is even
lower. Although treatment for a few biopsy diagnoses, such
as sarcoidosis or hemochromatosis, is beneficial, these diag-
noses are uncommon and usually apparent without endo-
myocardial biopsy . Myocarditis deserves special mention
.
Efficacy of immunosuppressive therapy is not yet estab-
lished in this disease . Clearly, a biopsy diagnosis need not be
sought in all patients suspected to have myocarditis, and
treatment cannot be considered routine if the diagnosis is
made .
Although prognostically accurate informa .,Ioon way be
derived by endomyocardial biopsy in some caw, 1 person-
ally have not found the histologic prognosis to be as useful as
shoit-term observation of the patient . Two exceptions are
the biopsy estimation of tolerability of additional anthracy-
cline therapy, and the differential diagnosis of apparently
idiopathic ventricular tachycardia or sudden death, in which
a diagnosis of myocarditis in a normal or minimally dilated
heart will dissuade me from aggressive management, such as
defibrillator/cardioverter implantation, in anticipation of
spontaneous improvement .
Kasper and associates recognize the selected nature of
their series . Their objective was to characterize the causes
of dilated cardiomyopathy in a referred population . Clearly,
biopsy was an absolutely necessary tool in that research
endeavor. By persisting in their use of endomyocardial
biopsy in this large series, they have accomplished the
important demonstration that biopsy infrequently provides a
treatment-responsive diagnosis . They identified four patients
with sarcoidosis, eight with steroid-responsive autoimmune
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disease and three with hemochromatosis ; in total, 2 .2 of
the group had treatable disease .
Kasper and colleagues wisely avoided delving into con-
troversy concerning applicability of endomyocardial biopsy .
Their objective was not to explore the clinical utility of
cardiac biopsy, which clearly, must be distinguished from its
utility as a research tool .
The fact that dilated cardiomyopathy is "idiopathic" in
so many whether SO, 75 or more demands attention .
Idiopathic dilated cardiomyopathy is common and it occurs
in young, productive people the mean age in the Johns
Hopkins series was 45 years . Morbidity and mortality are
extremely high . The only definitive treatment for most
patients, heart transplantation, is very expensive and avail-
able to only a small minority of patients with dilated cardio-
myopathy. We know too little to treat this disease effec-
tively. As a research tool, endomyocardial biopsy could be
helpful by providing diseased tissue for study, but we need a
more hopeful disposition for that tissue . In my view, at
present there are virtually no convincing scientific leads that
are likely to reveal the cause, and with it the cure, of this
disease . I hope that the growing deficiency of federal bio-
medical research funding and, especially, the destructively
misinformed preference for "practical" in place of funda-
mental research, have not arrived soon enough to arrest
development of the new knowledge that will be needed to
remedy the second most common disease of the heart .
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